LOG IN
SIGN UP
MARKET
JAGX
JAGX
Jaguar Health Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
0.3559
+0.0444
+14.25%
Opening 10:41 06/29 EDT
OPEN
0.3300
PREV CLOSE
0.3115
HIGH
0.3589
LOW
0.3205
VOLUME
5.58M
TURNOVER
1.05M
52 WEEK HIGH
5.19
52 WEEK LOW
0.2700
MARKET CAP
27.71M
P/E (TTM)
-0.2756
1D
5D
1M
3M
1Y
5Y
Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jaguar Health (NASDAQ:JAGX) stock rose ~5% on June 29 after t...
Seekingalpha · 9h ago
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China
0 million in unregistered equity infusion, over next 24 monthsService agreement of up to $5.0 million payable in unregistered Jaguar stock to SynWorld to support approval of crofelemer in China, providing Jaguar Health with up to 80% of profitsSAN FRANCISC...
ACCESSWIRE · 10h ago
Jaguar Health Teams Up With SynWorld to Make Canalevia Available in China; Shares Rise
MT Newswires · 11h ago
Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi
SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr.
ACCESSWIRE · 06/22 12:30
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.
Benzinga · 06/22 08:49
45 Stocks Moving In Tuesday's Mid-Day Session
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.8% to $10.31 as the company agreed to be taken private by TPG Capital,.
Benzinga · 06/21 16:03
24 Stocks Moving in Tuesday's Pre-Market Session
Gainers Valneva SE (NASDAQ: VALN) shares rose 83.6% to $25.18 in pre-market trading following Pfizer agreement to acquire an 8.1% stake.
Benzinga · 06/21 10:04
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider.
Benzinga · 06/15 16:32
No Data
Learn about the latest financial forecast of JAGX. Analyze the recent business situations of Jaguar Health Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 2 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average JAGX stock price target is 10.88 with a high estimate of 15.00 and a low estimate of 6.75.
Current 0.3199
EPS
Actual
Estimate
-0.32-0.24-0.16-0.08
Institutional Holdings
Institutions: 36
Institutional Holdings: 5.57M
% Owned: 7.05%
Shares Outstanding: 77.86M
TypeInstitutionsShares
Increased
8
589.60K
New
10
1.90M
Decreased
9
1.28M
Sold Out
6
212.26K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.70%
Pharmaceuticals & Medical Research
+0.64%
Key Executives
Non-Executive Chairman/Independent Director
James Bochnowski
President/Chief Executive Officer/Director
Lisa Conte
Chief Financial Officer
Carol Lizak
Chief Scientific Officer
Pravin Chaturvedi
Chief Compliance Officer/General Counsel
Jonathan Wolin
Other
Ian Wendt
Secretary
Steven King
Independent Director
Gregory Divis
Independent Director
John Micek
Independent Director
Jonathan Siegel
No Data
No Data
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceutical company. The Company is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The Company operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.
Webull offers kinds of Jaguar Health Inc stock information, including NASDAQ:JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.